Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma (NEXTAR)

Bayer

Status: Completed

Conditions: Carcinoma, Renal Cell

Treatments: Drug: Sorafenib (Nexavar, BAY 43-9006)

Study type: Observational

Funder types: Industry

Identifiers

NCT01508364

16091

NX1111 (Other Identifier)

Details and patient eligibility

About

This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.

Enrollment: 20 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar.
• Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment.

Exclusion criteria

• Prior targeted therapy for RCC
• Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).

Trial design

20 participants in 1 patient group

Group 1

Treatment:

Drug: Sorafenib (Nexavar, BAY 43-9006)